Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015', provides an overview of the Leishmaniasis (Kala-Azar)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Leishmaniasis (Kala-Azar) Overview 10
Therapeutics Development 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 14
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Leishmaniasis (Kala-Azar) - Products under Development by Companies 17
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 19
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 20
Advinus Therapeutics Ltd. 20
Anacor Pharmaceuticals, Inc. 21
Dafra Pharma International Ltd. 22
Georgia Tech Research Corporation 23
iCo Therapeutics Inc. 24
Merck KGaA 25
Mologen AG 26
Nanomerics Ltd 27
Sanofi 28
Takeda Pharmaceutical Company Limited 29
Zydus Cadila Healthcare Limited 30
Leishmaniasis (Kala-Azar) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
amphotericin b - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
amphotericin B - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
amphotericin b NanoDisk - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AS-605240 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CDRI-99/288 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
corifungin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
fexinidazole - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Indotecan hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
KVH-14 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
leishmaniasis vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
leishmaniasis vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
leishmaniasis vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Methoxycoronaridine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MGN-1331 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NPC-1161B - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Oleylphosphocholine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
pegylated amphotericin B - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
S-010269 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule for Leishmaniasis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule for Leishmaniasis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule for Visceral Leishmaniasis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Infectious Disease and Oncology - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules for Infectious Diseases - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules for Infectious Diseases - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules for Leishmaniasis - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules for Leishmaniasis - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules for Protozoal Infections - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Visceral Leishmaniasis - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
VGP-106 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
visceral leishmaniasis vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
VL-2098 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 82
Leishmaniasis (Kala-Azar) - Dormant Projects 84
Leishmaniasis (Kala-Azar) - Discontinued Products 85
Leishmaniasis (Kala-Azar) - Product Development Milestones 86
Featured News & Press Releases 86
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 86
Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 86
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 86
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 88
Nov 11, 2013: Paladin Announces Extension of the Impavido PDUFA Date by Three Months 88
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 88
Dec 17, 2012: PATH's Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 89
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 89
Mar 06, 2012: 10 million boost for neglected tropical disease research at Dundee 90
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015 11
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H1 2015 20
Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 21
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H1 2015 22
Leishmaniasis (Kala-Azar) - Pipeline by Georgia Tech Research Corporation, H1 2015 23
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2015 24
Leishmaniasis (Kala-Azar) - Pipeline by Merck KGaA, H1 2015 25
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2015 26
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2015 27
Leishmaniasis (Kala-Azar) - Pipeline by Sanofi, H1 2015 28
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 29
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H1 2015 82
Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2015 84
Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2015 85